News

September 12, 2017September 12, 2017

Ionis’ Antisense Therapy Shows Promising Results when Combined with Imfinzi in Head and Neck Cancers

News

Ionis Pharmaceuticals’ IONIS-STAT3-2.5 (AZD9150) showed promising results when given in combination with AstraZeneca’s Imfinzi (durvalumab) to patients with refractory and metastatic head and neck cancer in a small clinical trial. The ... Read more

September 12, 2017September 12, 2017

Keytruda Continues to Show Promise in Advanced Stomach Cancer Patients, Updated KEYNOTE-059 Data Show

News

Keytruda (pembrolizumab) is safe and has shown promising anti-tumor activity in patients with advanced gastric or gastroesophageal junction (GEJ) cancer, according to data presented at the European Society for Medical Oncology (ESMO) ... Read more

September 11, 2017September 11, 2017

Opdivo Improves Long-Term Survival in Advanced Lung Cancer, Data Show

News

Opdivo (nivolumab) outperformed the cancer drug Taxotere (docetaxel) in clinical trials of advanced and earlier treated lung cancer, with survival rates about double those seen with the older treatment after ... Read more

September 11, 2017

Imugene Begins Phase 1b/2 Clinical Trial of HER-Vaxx Vaccine for Stomach Cancer

News

The first patient has been dosed in a Phase 1b/2 trial evaluating Imugene’s stomach cancer vaccine HER-Vaxx. Researchers are still recruiting participants. They hope to enroll 18 patients at eight locations ... Read more

September 8, 2017September 8, 2017

Opdivo, Yervoy Combo Lengthens Survival Time in Renal Cell Carcinoma Patients, Supporting Early Trial End

News

The combination of Opdivo (nivolumab) and Yervoy (ipilimumab) was more effective in prolonging the lives of newly diagnosed metastatic renal cell carcinoma patients than the current standard of care, Sutent (sunitinib), new data from ... Read more

September 7, 2017September 7, 2017

FDA Suspends UCART123 Trials After Patient Death

News

The U.S. Food and Drug Administration (FDA) has suspended two Phase 1 trials assessing Cellectis’ CAR T-cell therapy UCART123 in acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN) after the first ... Read more

September 6, 2017September 6, 2017

Keytruda Approved in Europe for Certain Bladder Cancer Patients

News

The European Commission (EC) has approved Keytruda (pembrolizumab) for the treatment of certain patients with locally advanced or metastatic urothelial carcinoma, according to the therapy’s maker, Merck, known as MSD outside the United ... Read more

September 5, 2017September 5, 2017

Bristol-Myers Squibb, Daiichi Sankyo to Jointly Test Opdivo/DS-8201 Combo in HER2+ Metastatic Breast, Bladder Cancers

News

Bristol-Myers Squibb has formed a partnership with Japan’s Daiichi Sankyo to test Opdivo (nivolumab) in combination with DS-8201 in HER2-positive metastatic breast and bladder cancer. Opdivo, a blockbuster anti-PD-1 immune checkpoint inhibitor, is already approved ... Read more

September 1, 2017

Shattuck-Takeda Partnership Will Involve Double-barreled Cancer-fighting Therapies

News

Shattuck Labs‘ double-barreled immuno-oncology approach to fighting cancer will be at the heart of a new therapy-development partnership it has formed with Takeda Pharmaceutical Company. Agonist Redirected Checkpoint, or ARC, is the name ... Read more

August 31, 2017

Canakinumab Reduces Incidents of Lung Cancer and Associated Mortalities, Study Finds

News

Targeting the interleukin-1β innate immunity pathway through the use of the anti-inflammatory drug canakinumab (ACZ885) led to a significant reduction in lung cancer and lung cancer mortality, new study shows. ... Read more